Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude sur le zanidatamab en association avec une chimiothérapie plus ou moins tislelizumab chez des patients atteints de cancers gastriques et œsophagiens avancés ou métastatiques HER2-positifs (HERIZON-GEA-01)

18 novembre 2026 mis à jour par: Jazz Pharmaceuticals

Une étude multicentrique randomisée de phase 3 sur le zanidatamab en association avec une chimiothérapie avec ou sans tislelizumab chez des sujets atteints d'un adénocarcinome gastro-œsophagien localement avancé ou métastatique HER2-positif non résécable

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.

The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

920

Phase

  • Phase 3

Accès étendu

Plus disponible en dehors de l'essai clinique. Voir enregistrement d'accès étendu.

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Pretoria, Afrique du Sud, 0184
        • Wilgers Oncology Centre
    • Hesse
      • Frankfurt am Main, Hesse, Allemagne, 60488
        • Institut für Klinisch-Onkologische Forschung
      • Buenos Aires, Argentine, C1181ACH
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentine, 1264
        • Hospital de Gastroenterología Dr Bonorino Udaondo
      • Buenos Aires, Argentine, C1012
        • Instituto de Investigaciones Metabólicas - IDIM
      • Córdoba, Argentine, X5000HXL
        • Fundación Centro de Medicina Nuclear y Molecular ER
      • Córdoba, Argentine, X5008HHW
        • Centro Médico Privado CEMAIC
      • Pergamino, Argentine, 2700
        • Centro de Investigación Pergamino S.A.
      • Viedma, Argentine, R8500ACE
        • Centro de Investigación Clínica - Clínica Viedma
      • Bedford Park, Australie, 5042
        • Flinders Medical Centre
      • Heidelberg, Australie, 3084
        • Austin Health
      • Liverpool, Australie, 2170
        • Liverpool Hospital
      • Murdoch, Australie, 6150
        • Fiona Stanley Hospital
      • Bonheiden, Belgique, 2820
        • Imelda VZW
      • Brussels, Belgique, 1200
        • Cliniques Universitaires Saint-Luc
      • Ghent, Belgique, 9000
        • UZ Gent
      • Leuven, Belgique, 3000
        • UZ Leuven
      • Liège, Belgique, 4000
        • CHU de Liège
      • Barretos, Brésil, 14784-400
        • Centro Integrado de Pesquisa - CIP
      • Barretos, Brésil, 14784-400
        • Fundação Pio XII Hospital de Câncer de Barretos
      • Belo Horizonte, Brésil, 30130-090
        • Cenantron - Centro Avancado de Tratamento Oncologico Ltda
      • Brasília, Brésil, 70840-901
        • Centro de Pesquisas Clínicas/Fundação Doutor Amaral Carvalho
      • Fortaleza, Brésil, 60430-230
        • Instituto Do Câncer Do Ceará ICC
      • Porto Alegre, Brésil, 90050-170
        • Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
      • Porto Alegre, Brésil, 90050-170
        • Irmandade Da Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre, Brésil, 91350-200
        • Hospital Nossa Senhora Da Conceição
      • Santo André, Brésil, 09060-650
        • Núcleo de Pesquisa Clínica da Rede São Camilo
      • Sorocaba, Brésil, 18030-075
        • Instituto de Oncologia de Sorocaba
      • São Paulo, Brésil, 01246-000
        • Instituto do Cancer do Estado de São Paulo ICESP
      • Toronto, Canada, M5G 2C1
        • Princess Margaret Cancer Centre
      • Providencia, Chili, 7500000
        • Centro de Estudios Clínicos SAGA SpA
      • Santiago, Chili, 7500000
        • Sociedad Oncovida S.A
      • Santiago, Chili, 8150513
        • Icegclinic
      • Santiago, Chili, 8330336
        • BIOCINETIC SpA
      • Temuco, Chili, 4810469
        • Sociedad de Investigaciones Medicas Limitada
    • Region Metropolitan
      • Santiago, Region Metropolitan, Chili, 8420383
        • Centro Internacional de Estudios Clinicos CIEC
    • Santiago Metropolitan
      • Providencia, Santiago Metropolitan, Chili, 7500000
        • Fundación Arturo López Pérez (FALP) - PPDS
      • Beijing, Chine, 100142
        • Beijing Cancer Hospital
      • Beijing, Chine, 100191
        • Peking University Third Hospital
      • Beijing, Chine, 100021
        • Cancer Hospital Chinese Academy of Medical Sciences
      • Beijing, Chine, 101199
        • Beijing Luhe Hospital, Capital Medical University
      • Beijing, Chine, 100020
        • Beijing Chao-Yang Hospital, Capital Medical University
      • Bengbu, Chine, 233004
        • The First Affiliated Hospital of Bengbu Medical College
      • Changsha, Chine, 410031
        • Hunan Cancer Hospital
      • Changzhi, Chine, 046099
        • Changzhi People's Hospital
      • Changzhou, Chine, 213004
        • Changzhou First People's Hospital
      • Chengdu, Chine, 610042
        • Sichuan Cancer Hospital & Institute
      • Fuzhou, Chine, 350014
        • Fujian Cancer Hospital
      • Fuzhou, Chine, 350005
        • The First Affiliated Hospital of Fujian Medical University
      • Guangzhou, Chine, 510655
        • The Sixth Affiliated Hospital of Sun Yat-sen University
      • Guangzhou, Chine, 510055
        • Guangdong Provincial People's Hospital
      • Haikou, Chine, 570311
        • Hainan General Hospital
      • Hangzhou, Chine, 310016
        • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
      • Hangzhou, Chine, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Chine, 310003
        • The First Affiliated Hospital, College of Medicine, Zhejiang University
      • Hangzhou, Chine, 310017
        • Second Affiliated Hospital of Zhejiang University School of Medicine
      • Harbin, Chine, 150081
        • Harbin Medical University Cancer Hospital
      • Hefei, Chine, 230601
        • The Second Affiliated Hospital of Anhui Medical University
      • Hefei, Chine, 230031
        • Anhui Provincial Cancer Hospital
      • Hohhot, Chine, 01000
        • Affiliated Hospital of Inner Mongolia Medical University
      • Jinan, Chine, 250013
        • Jinan Central Hospital
      • Jinan, Chine, 250000
        • Shandong Cancer Hospital
      • Kunming, Chine, 650118
        • Yunnan Cancer Hospital
      • Lanzhou, Chine, 730050
        • Gansu Cancer Hospital
      • Lanzhou, Chine, 730013
        • The First Hospital of Lanzhou University
      • Nanchang, Chine, 330052
        • The First Affiliated Hospital of Nanchang University
      • Nanjing, Chine, 210008
        • Nanjing Drum Tower Hospital ,The Affiliated Hospital of Nanjing University Medical School
      • Qingdao, Chine, 266003
        • The Affiliated Hospital of Qingdao University
      • Shanghai, Chine, 200032
        • Fudan University Shanghai Cancer Center
      • Shanghai, Chine, 200080
        • Shanghai General Hospital
      • Shanghai, Chine, 200032
        • Fudan University Affiliated Zhongshan Hospital
      • Shanghai, Chine, 200025
        • Ruijin hospital Shanghai Jiao Tong University School of Medicine
      • Shenyang, Chine, 110801
        • Liaoning Cancer Hospital & Institute
      • Shijiazhuang, Chine, 50011
        • The Fourth Hospital of Hebei Medical University
      • Tianjin, Chine, 300060
        • Tianjin Medical University Cancer Institute & Hospital
      • Tianjin, Chine, 300041
        • Tianjin Medical University General Hospital
      • Tonghua, Chine, 143099
        • The Tonghua Central Hospital
      • Weihai, Chine, 264200
        • Weihai Municipal Hospital
      • Wenzhou, Chine, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, Chine, 430079
        • Hubei Cancer Hospital
      • Wuhan, Chine, 430023
        • Union Hospital Tongji Medical College HuaZhong University of Science and Technology
      • Wuxi, Chine, 214062
        • Affiliated Hospital of Jiangnan University
      • Xi'an, Chine, 710061
        • First Affiliated Hospital of Xi 'an Jiaotong University
      • Xiamen, Chine, 361003
        • The First Affiliated Hospital of Xiamen University
      • Yangzhou, Chine, 225001
        • Northern Jiangsu People's Hospital
      • Zhengzhou, Chine, 450052
        • The First Affiliated Hospital of Zhengzhou University
      • Zhengzhou, Chine, 450003
        • Henan Cancer Hospital
      • Ürümqi, Chine, 830026
        • Cancer Hospital affiliated to Xinjiang Medical University
      • Anyang-si, Corée du Sud, 14068
        • Hallym University Sacred Heart Hospital
      • Busan, Corée du Sud, 49201
        • Dong-A University Hospital
      • Daegu, Corée du Sud, 41404
        • Kyungpook National University Chilgok Hospital
      • Goyang-si, Corée du Sud, 10408
        • National Cancer Center
      • Incheon, Corée du Sud, 21565
        • Gachon University Gil Medical Center
      • Seongnam-si, Corée du Sud, 13620
        • Seoul National University Bundang Hospital
      • Seongnam-si, Corée du Sud, 13496
        • CHA Bundang Medical Center, CHA University
      • Seoul, Corée du Sud, 03080
        • Seoul National University Hospital
      • Seoul, Corée du Sud, 05505
        • Asan Medical Center
      • Seoul, Corée du Sud, 06351
        • Samsung Medical Center
      • Seoul, Corée du Sud, 03181
        • Kangbuk Samsung Hospital
      • Seoul, Corée du Sud, 02841
        • Korea University Anam Hospital
      • Seoul, Corée du Sud, 08308
        • Korea University Guro Hospital
      • Seoul, Corée du Sud, 03080
        • The Catholic University of Korea, Seoul St. Mary's Hospital
      • Seoul, Corée du Sud, 03686
        • Severance Hospital Yonsei University Health System - PPDS
      • Seoul, Corée du Sud, 06229
        • Gangnam Severance Hospital, Yonsei University Health System
      • Badalona, Espagne, 8915
        • Hospital Universitario Germans Trias i Pujol
      • Barcelona, Espagne, 08035
        • Hospital Universitario Vall d'Hebron - PPDS
      • Girona, Espagne, 17007
        • Hospital Universitari de Girona Dr Josep Trueta
      • L'Hospitalet de Llobregat, Espagne, 08908
        • Institut Català d'Oncologia (Hospital Duran y Reynals)
      • Madrid, Espagne, 28034
        • Hospital Universitario Ramon y Cajal
      • Madrid, Espagne, 28046
        • Hospital Universitario La Paz - PPDS
      • Málaga, Espagne, 29010
        • Hospital Regional Universitario de Malaga - Hospital General
      • Salamanca, Espagne, 32911
        • Complejo Asistencial Universitario de Salamanca - H. Clinico
      • Santander, Espagne, 39008
        • Hospital Universitario Marques de Valdecilla
      • Seville, Espagne, 41009
        • Hospital Universitario Virgen Macarena
      • Zaragoza, Espagne, 50009
        • Hospital Universitario Miguel Servet
    • Barcelona
      • Sabadell, Barcelona, Espagne, 08208
        • Corporacio Sanitaria Parc Tauli
    • Navarre
      • Pamplona, Navarre, Espagne, 31008
        • Complejo Hospitalario de Navarra
      • Tallinn, Estonie, 13419
        • North Estonia Medical Centre Foundation
      • Avignon, France, 84000
        • Sainte-Catherine, Institut du Cancer Avignon Provence
      • Bordeaux, France, 33000
        • EDOG - Institut Bergonie - PPDS
      • Dijon, France, 21079
        • Universite de Bourgogne - Faculte de Medecine - IN
      • Grenoble, France, 38043
        • Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon
      • Lyon, France, 69008
        • Centre Léon Berard
      • Nantes, France, 44805
        • EDOG Institut de Cancerologie de l'Ouest - PPDS
      • Poitiers, France, 86021
        • CHRU de Poitiers La Miletrie
      • Rennes, France, 35000
        • EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS
      • Saint-Priest-en-Jarez, France, 42270
        • CHRU de Brest - Hopital Morvan
      • Toulouse, France, 69437
        • Hôpital de Rangueil
      • Villejuif, France, 94800
        • Hôpital Saint Antoine
    • Gironde
      • Pessac, Gironde, France, 33600
        • CHU de Bordeaux - Hopital Haut Leveque
      • Athens, Grèce, 124 64
        • Attikon University General Hospital
      • Thessaloniki, Grèce, 552 36
        • Agios Loucas Clinic SA
      • Thessaloniki, Grèce, 54622
        • Bioclinic Thessaloniki Oncology Department
      • Thessaloniki, Grèce, 57001
        • Interbalkan Medical Center of Thessaloniki Oncology Department
      • Guatemala City, Guatemala, 01010
        • Clinica Medica Especializada CELAN
      • Guatemala City, Guatemala, 01015
        • Grupo Medico Angeles
      • Salcajá, Guatemala, 09002
        • Centro Medico Integral de Cancerologia CEMIC
      • Tbilisi, Géorgie, 0112
        • Research Institute of Clinical Medicine
      • Tbilisi, Géorgie, 6000
        • High Technology Hospital MedCenter Ltd
      • Bhubaneswar, Inde, 751019
        • All India Institute of Medical Sciences, Bhubaneswar
      • Gūrgaon, Inde, 122003
        • Artemis Hospital
      • Hyderabad, Inde, 500004
        • MNJ Institute of Oncology and Regional Cancer Centre
      • New Delhi, Inde, 110076
        • Indraprastha Apollo Hospitals
      • Patna, Inde, 800014
        • Regional Cancer Centre Indira Gandhi Institute of Medical Sciences
      • Vijayawada, Inde, 520002
        • HCG City Cancer Center
      • Dublin, Irlande, 8
        • St James's Hospital
      • Bologna, Italie, 40138
        • Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi
      • Candiolo, Italie, 10060
        • Fondazione del Piemonte per l'Oncologia (IRCCS)
      • Genova, Italie, 16132
        • Ospedale Policlinico San Martino
      • Meldola, Italie, 47014
        • Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
      • Milan, Italie, 20132
        • Ospedale San Raffaele S.r.l. - PPDS
      • Milan, Italie, 20162
        • ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda
      • Milan, Italie, 20133
        • Istituto Nazionale Dei Tumori
      • Modena, Italie, 41124
        • Azienda Ospedaliero Universitaria Di Modena Policlinico
      • Reggio Emilia, Italie, 43100
        • Arcispedale Santa Maria Nuova
      • Rome, Italie, 00168
        • Fondazione Policlinico Universitario A Gemelli
      • Verona, Italie, 37134
        • Centro Ricerche Cliniche Di Verona
      • Vicenza, Italie, 36100
        • Azienda ULSS 8 "Berica" - Ospedale San Bortolo
      • Chūōku, Japon, 104-0045
        • National Cancer Center Hospital
      • Fukuoka, Japon, 811-1395
        • National Hospital Organization Kyushu Cancer Center
      • Ina, Japon, 362-0806
        • Saitama Cancer Center
      • Matsuyama, Japon, 791-0245
        • Shikoku Cancer Center
      • Osaka, Japon, 540-0008
        • Osaka International Cancer Institute
      • Tokyo, Japon, 135-8550
        • The Cancer Institute Hospital of Japanese Foundation For Cancer Research
      • Ōsaka-sayama, Japon, 589-0014
        • Kindai University Hospital
    • Chiba
      • Chiba, Chiba, Japon, 260-0801
        • Chiba Cancer Center
      • Kashiwa-shi, Chiba, Japon, 277-8577
        • National Cancer Center Hospital East
    • Gihu
      • Gifu, Gihu, Japon, 501-1112
        • Gifu University Hospital
    • Gunma
      • Ota-shi, Gunma, Japon, 373-8550
        • Gunma Prefectural Cancer Center
    • Hyôgo
      • Akashi-shi, Hyôgo, Japon, 673-8558
        • Hyogo Cancer Center
    • Ibaraki
      • Kasama-Shi, Ibaraki, Japon, 309-1793
        • Ibaraki Prefectural Central Hospital
    • Kagawa-ken
      • Kita-Gun Miki-Cho, Kagawa-ken, Japon, 761-0701
        • Kagawa University Hospital
    • Kanagawa
      • Yokohama-Shi Asahi-Ku, Kanagawa, Japon, 241-0815
        • Kanagawa Cancer Center
    • Kumamoto
      • Chuo-Ku, Kumamoto, Japon, 860-8556
        • Kumamoto University Hospital - Honjo-Kuhonji Campus A
    • Kyoto-shi
      • Sakyo-ku, Kyoto-shi, Japon, 606-8507
        • Kyoto University Hospital
    • Miyagi
      • Osaki-Shi, Miyagi, Japon, 989-6136
        • Osaki Citizen Hospital
    • Okayama-ken
      • Kurashiki-Shi, Okayama-ken, Japon, 710-0052
        • Kurashiki Central Hospital
    • Osaka
      • Suita-Shi, Osaka, Japon, 565-0871
        • Osaka University Hospital
      • Takatsuki-Shi, Osaka, Japon, 569-8686
        • Osaka Medical and Pharmaceutical University Hospital
    • Tokyo
      • Shinjuku-Ku, Tokyo, Japon, 160-8582
        • Keio University Hospital
      • Almada, Le Portugal, 2801-951
        • Hospital Garcia de Orta
      • Coimbra, Le Portugal, 3000-459
        • Centro Hospitalar E Universitário de Coimbra EPE
      • Guimarães, Le Portugal, 4830-044
        • Hospital Senhora da Oliveira - Guimaraes, E.P.E
      • Lisbon, Le Portugal, 1649-035
        • Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria
      • Matosinhos Municipality, Le Portugal, 4454-509
        • Unidade Local de Saúde de Matosinhos SA
      • Porto, Le Portugal, 4200-072
        • Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
      • Porto, Le Portugal, 4099-001
        • Centro Hospitalar do Porto EPE
      • George Town, Malaisie, 10990
        • Hospital Pulau Pinang
      • Kuching, Malaisie, 93586
        • Sarawak General Hospital
      • Putrajaya, Malaisie, 62675
        • National Cancer Institute ( Institut Kanser Negara)
      • Mexico City, Mexique, 03100
        • Health Pharma Professional Research S.A de C.V.
      • Monterrey, Mexique, 64460
        • Hospital Universitario Dr. Jose Eleuterio González
      • Oaxaca City, Mexique, 68020
        • Centro de Investigacion Clinica de Oaxaca
      • Eindhoven, Pays-Bas, 5623 EJ
        • Catharina Hospital
      • Leiden, Pays-Bas, 2333 ZA
        • Leids Universitair Medisch Centrum
      • Tilburg, Pays-Bas, 5042 AD
        • ETZ-Elisabeth
      • Lodz, Pologne, 93-513
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
      • Warsaw, Pologne, 02-034
        • Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie
      • Bucharest, Roumanie, 022328
        • Fundeni Clinical Institute
      • Cluj-Napoca, Roumanie, 400015
        • Prof Dr I Chiricuta Institute of Oncology - PPDS
      • Cluj-Napoca, Roumanie, 400641
        • Medisprof SRL
      • Craiova, Roumanie, 200347
        • Oncology Center Sfantul Nectarie
      • Bristol, Royaume-Uni, BS2 8ED
        • Bristol Haematology and Oncology Centre
      • Edinburgh, Royaume-Uni, EH4 2XU
        • Western General Hospital Edinburgh - PPDS
      • Leeds, Royaume-Uni, LS9 7TF
        • St James University Hospital
      • London, Royaume-Uni, SE1 9RT
        • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
      • London, Royaume-Uni, SW7 3RP
        • Royal Marsden Hospital - London
      • London, Royaume-Uni, SW7 3RP
        • Royal Marsden Hospital - Surrey
      • Peterborough, Royaume-Uni, PE3 9GZ
        • Edith Cavell Hospital
      • Sheffield, Royaume-Uni, S10 2SJ
        • Weston Park Cancer Centre
      • Belgrade, Serbie, 11070
        • Clinical Hospital Center Bezanijska Kosa
      • Belgrade, Serbie, 11000
        • University Clinical Center of Serbia - PPDS
      • Kamenitz, Serbie, 21204
        • Oncology Institute of Vojvodina
      • Niš, Serbie, 18000
        • University Clinical Center Nis
      • Singapore, Singapour, 258500
        • National Cancer Center Singapore
      • Taichung, Taïwan, 404472
        • China Medical University Hospital
      • Taipei, Taïwan, 11217
        • Taipei Veterans General Hospital
      • Hat Yai, Thaïlande, 90110
        • Songklanagarind Hospital
      • Khon Kaen, Thaïlande, 40000
        • Srinagarind Hospital, Khon Kaen University
      • Lak Si, Thaïlande, 10210
        • Chulaborn Hospital
      • Ankara, Turquie (Türkiye), 06230
        • Hacettepe Universitesi Kanser Enstitusu
      • Edirne, Turquie (Türkiye), 22030
        • Trakya University Medical Faculty
      • Izmir, Turquie (Türkiye), 35220
        • Dokuz Eylul Universitesi
      • Seyhan, Turquie (Türkiye), 01130
        • Acibadem Adana Hospital
      • Trabzon, Turquie (Türkiye), 61310
        • Medical Park Trabzon Yildizli
      • Yenimahalle, Turquie (Türkiye), 06200
        • Dr. Abdurrahman Yurtaslan Ankara Onkology Training and Research Hospital
      • Dnipropetrovsk, Ukraine, 49102
        • Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council - PPDS

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Histologically confirmed unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Subjects with esophageal adenocarcinoma must not be eligible for combined chemoradiotherapy at the time of enrollment
  • Assessable (measurable or non-measurable) disease as defined by RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, assessed within 3 days prior to randomization
  • Adequate organ function
  • Left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA)

Exclusion Criteria:

  • Prior treatment with a HER2-targeted agent, with the exception of subjects who received HER2-targeted treatment for breast cancer > 5 years prior to initial diagnosis of GEA
  • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Prior treatment with systemic antineoplastic therapy or intraperitoneal chemotherapy for unresectable locally advanced, recurrent or metastatic GEA
  • Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks prior to randomization. Stable, treated brain metastases are allowed (defined as subjects who are completely off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks prior to randomization)
  • Known history of or ongoing leptomeningeal disease (LMD)
  • Known additional malignancy that is not considered cured or that has required treatment within the past 3 years
  • Known active hepatitis
  • Any history of human immunodeficiency virus (HIV) infection
  • Known SARS-CoV-2 infection; subjects with prior infection that has resolved per local institutions' requirements and screening guidance are eligible
  • QTc Fridericia (QTcF) > 470 ms
  • Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Arm A

Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)

Administered intravenously (IV)

Autres noms:
  • Herceptine®

Administered orally (PO bid)

Administered IV

Administered IV

Administered IV

Expérimental: Arm B

Zanidatamab plus physician's choice of CAPOX or FP

Administered orally (PO bid)

Administered IV

Administered IV

Administered IV

Administered IV

Autres noms:
  • ZW25
  • JZP598
  • Ziihera®
Expérimental: Arm C

Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP

Administered orally (PO bid)

Administered IV

Administered IV

Administered IV

Administered IV

Autres noms:
  • ZW25
  • JZP598
  • Ziihera®

Administered IV

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression-free survival (PFS) by BICR
Délai: Up to 2.5 years

The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause

Up to 2.5 years
Overall survival
Délai: Up to 3.5 years

The time from randomization to death due to any cause

Up to 3.5 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Concentration sérique de zanidatamab et de tislelizumab
Délai: Jusqu'à 2 ans
Jusqu'à 2 ans
Confirmed objective response rate (ORR) by BICR
Délai: Up to 2.5 years

Number of patients who achieved a best overall response of complete response (CR) or (PR) as determined per RECIST 1.1 as assessed by BICR

Up to 2.5 years
Duration of response (DOR) by BICR
Délai: Up to 2.5 years

The time from the first objective response (CR or PR) per BICR to documented progressive disease per RECIST 1.1 as assessed by BICR or death from any cause

Up to 2.5 years
PFS per Investigator assessment
Délai: Up to 2.5 years

The time from randomization to the date of documented disease progression (per RECIST 1.1) as assessed by Investigator or death from any cause

Up to 2.5 years
Confirmed ORR per Investigator assessment
Délai: Up to 2.5 years

Number of patients who achieved a best overall response of CR or PR as determined per RECIST 1.1 as assessed by Investigator

Up to 2.5 years
DOR per Investigator assessment
Délai: Up to 2.5 years

The time from the first objective response (CR or PR) per Investigator to documented progressive disease per RECIST 1.1 as assessed by Investigator or death from any cause

Up to 2.5 years
Assessment of Contribution of Components based on Progression-free Survival (PFS) by BICR
Délai: Up to 2.5 years

The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause

Up to 2.5 years
Assessment of Contribution of Components based on Overall Survival
Délai: Up to 3.5 years

The time from randomization to death due to any cause

Up to 3.5 years
Incidence of adverse events
Délai: Up to 2 years

Number of subjects who experienced adverse events or serious adverse events

Up to 2 years
Incidence of clinical laboratory abnormalities
Délai: Up to 2 years

Number of patients who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

Up to 2 years
Health-related quality of life (HRQoL) as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (core cancer questionnaire) C30 (QLQ-C30)
Délai: Up to 2.5 years

Changes from baseline in the EORTC QLQ-C30 scores

Up to 2.5 years
HRQoL as assessed by the EORTC Quality of Life Questionnaire (oesophago-gastric module) OG25 (QLQ-OG25)
Délai: Up to 2.5 years

Changes from baseline in the EORTC QLQ-OG25 scores

Up to 2.5 years
HRQoL as assessed by the EuroQol 5-dimensions 5-levels (EQ-5D-5L) questionnaire
Délai: Up to 2.5 years

Changes from baseline in the EORTC EQ-5D-5L questionnaire scores

Up to 2.5 years
Incidence of anti-drug antibodies (ADAs)
Délai: Up to 2 years

Number of patients who develop ADAs

Up to 2 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

2 décembre 2021

Achèvement primaire (Réel)

15 juillet 2026

Achèvement de l'étude (Estimé)

30 septembre 2027

Dates d'inscription aux études

Première soumission

5 novembre 2021

Première soumission répondant aux critères de contrôle qualité

3 décembre 2021

Première publication (Réel)

9 décembre 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

18 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • ZWI-ZW25-301
  • 2021-000296-36 (Numéro EudraCT)
  • jRCT2061230026 (Identificateur de registre: Japan Registry for Clinical Trials (jRCT))
  • 2023-510319-20-00 (Ctis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .